Ran GTPase-activating protein 1 is a therapeutic target in diffuse large B-cell lymphoma

Kung Chao Chang, Wei Chao Chang, Yao Chang, Liang Yi Hung, Chien Hsien Lai, Yu Min Yeh, Yu Wei Chou, Chung Hsuan Chen

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Lymphoma-specific biomarkers contribute to therapeutic strategies and the study of tumorigenesis. Diffuse large Bcell lymphoma (DLBCL) is the most common type of malignant lymphoma. However, only 50% of patients experience long-term survival after current treatment; therefore, developing novel therapeutic strategies is warranted. Comparative proteomic analysis of two DLBCL lines with a B-lymphoblastoid cell line (LCL) showed differential expression of Ran GTPase-activating protein 1 (RanGAP1) between them, which was confirmed using immunoblotting. Immunostaining showed that the majority of DLBCLs (92%, 46/50) were RanGAP1+, while reactive lymphoid hyperplasia (n = 12) was RanGAP1+ predominantly in germinal centers. RanGAP1 was also highly expressed in other B-cell lymphomas (BCL, n = 180) with brisk mitotic activity (B-lymphoblastic lymphoma/leukemia: 93%, and Burkitt lymphoma: 95%) or cell-cycle dysregulation (mantle cell lymphoma: 83%, and Hodgkin's lymphoma 91%). Interestingly, serum RanGAP1 level was higher in patients with high-grade BCL (1.71 ± 2.28 ng/mL, n = 62) than in low-grade BCL (0.75 ± 2.12 ng/mL, n = 52) and healthy controls (0.55 ± 1.58 ng/mL, n = 75) (high-grade BCL vs. low-grade BCL, p = 0.002; high-grade BCL vs. control, p < 0.001, Mann-Whitney U test). In vitro, RNA interference of RanGAP1 showed no effect on LCL but enhanced DLBCL cell death (41% vs. 60%; p = 0.035) and cell-cycle arrest (G0/G1: 39% vs. 49%, G2/M: 19.0% vs. 7.5%; p = 0.030) along with decreased expression of TPX2 and Aurora kinases, the central regulators of mitotic cell division. Furthermore, ON 01910.Na (Estybon), a multikinase inhibitor induced cell death, mitotic cell arrest, and hyperphosphorylation of RanGAP1 in DLBCL cell lines but no effects in normal B and T cells. Therefore, RanGAP1 is a promising marker and therapeutic target for aggressive B-cell lymphoma, especially DLBCL.

Original languageEnglish
Article numbere79863
JournalPloS one
Volume8
Issue number11
DOIs
Publication statusPublished - 2013 Nov 6

Fingerprint

ran GTP-Binding Protein
GTPase-activating proteins
GTPase-Activating Proteins
Lymphoma, Large B-Cell, Diffuse
lymphoma
B-lymphocytes
Cells
Lymphoma
therapeutics
Cell death
Therapeutics
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Cell Line
Cell Death
Aurora Kinases
cell lines
Pseudolymphoma
G1 Phase Cell Cycle Checkpoints
Mantle-Cell Lymphoma
Germinal Center

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)
  • General

Cite this

Chang, Kung Chao ; Chang, Wei Chao ; Chang, Yao ; Hung, Liang Yi ; Lai, Chien Hsien ; Yeh, Yu Min ; Chou, Yu Wei ; Chen, Chung Hsuan. / Ran GTPase-activating protein 1 is a therapeutic target in diffuse large B-cell lymphoma. In: PloS one. 2013 ; Vol. 8, No. 11.
@article{815adcb135de464c9fcc65d594ca556a,
title = "Ran GTPase-activating protein 1 is a therapeutic target in diffuse large B-cell lymphoma",
abstract = "Lymphoma-specific biomarkers contribute to therapeutic strategies and the study of tumorigenesis. Diffuse large Bcell lymphoma (DLBCL) is the most common type of malignant lymphoma. However, only 50{\%} of patients experience long-term survival after current treatment; therefore, developing novel therapeutic strategies is warranted. Comparative proteomic analysis of two DLBCL lines with a B-lymphoblastoid cell line (LCL) showed differential expression of Ran GTPase-activating protein 1 (RanGAP1) between them, which was confirmed using immunoblotting. Immunostaining showed that the majority of DLBCLs (92{\%}, 46/50) were RanGAP1+, while reactive lymphoid hyperplasia (n = 12) was RanGAP1+ predominantly in germinal centers. RanGAP1 was also highly expressed in other B-cell lymphomas (BCL, n = 180) with brisk mitotic activity (B-lymphoblastic lymphoma/leukemia: 93{\%}, and Burkitt lymphoma: 95{\%}) or cell-cycle dysregulation (mantle cell lymphoma: 83{\%}, and Hodgkin's lymphoma 91{\%}). Interestingly, serum RanGAP1 level was higher in patients with high-grade BCL (1.71 ± 2.28 ng/mL, n = 62) than in low-grade BCL (0.75 ± 2.12 ng/mL, n = 52) and healthy controls (0.55 ± 1.58 ng/mL, n = 75) (high-grade BCL vs. low-grade BCL, p = 0.002; high-grade BCL vs. control, p < 0.001, Mann-Whitney U test). In vitro, RNA interference of RanGAP1 showed no effect on LCL but enhanced DLBCL cell death (41{\%} vs. 60{\%}; p = 0.035) and cell-cycle arrest (G0/G1: 39{\%} vs. 49{\%}, G2/M: 19.0{\%} vs. 7.5{\%}; p = 0.030) along with decreased expression of TPX2 and Aurora kinases, the central regulators of mitotic cell division. Furthermore, ON 01910.Na (Estybon), a multikinase inhibitor induced cell death, mitotic cell arrest, and hyperphosphorylation of RanGAP1 in DLBCL cell lines but no effects in normal B and T cells. Therefore, RanGAP1 is a promising marker and therapeutic target for aggressive B-cell lymphoma, especially DLBCL.",
author = "Chang, {Kung Chao} and Chang, {Wei Chao} and Yao Chang and Hung, {Liang Yi} and Lai, {Chien Hsien} and Yeh, {Yu Min} and Chou, {Yu Wei} and Chen, {Chung Hsuan}",
year = "2013",
month = "11",
day = "6",
doi = "10.1371/journal.pone.0079863",
language = "English",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "11",

}

Ran GTPase-activating protein 1 is a therapeutic target in diffuse large B-cell lymphoma. / Chang, Kung Chao; Chang, Wei Chao; Chang, Yao; Hung, Liang Yi; Lai, Chien Hsien; Yeh, Yu Min; Chou, Yu Wei; Chen, Chung Hsuan.

In: PloS one, Vol. 8, No. 11, e79863, 06.11.2013.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Ran GTPase-activating protein 1 is a therapeutic target in diffuse large B-cell lymphoma

AU - Chang, Kung Chao

AU - Chang, Wei Chao

AU - Chang, Yao

AU - Hung, Liang Yi

AU - Lai, Chien Hsien

AU - Yeh, Yu Min

AU - Chou, Yu Wei

AU - Chen, Chung Hsuan

PY - 2013/11/6

Y1 - 2013/11/6

N2 - Lymphoma-specific biomarkers contribute to therapeutic strategies and the study of tumorigenesis. Diffuse large Bcell lymphoma (DLBCL) is the most common type of malignant lymphoma. However, only 50% of patients experience long-term survival after current treatment; therefore, developing novel therapeutic strategies is warranted. Comparative proteomic analysis of two DLBCL lines with a B-lymphoblastoid cell line (LCL) showed differential expression of Ran GTPase-activating protein 1 (RanGAP1) between them, which was confirmed using immunoblotting. Immunostaining showed that the majority of DLBCLs (92%, 46/50) were RanGAP1+, while reactive lymphoid hyperplasia (n = 12) was RanGAP1+ predominantly in germinal centers. RanGAP1 was also highly expressed in other B-cell lymphomas (BCL, n = 180) with brisk mitotic activity (B-lymphoblastic lymphoma/leukemia: 93%, and Burkitt lymphoma: 95%) or cell-cycle dysregulation (mantle cell lymphoma: 83%, and Hodgkin's lymphoma 91%). Interestingly, serum RanGAP1 level was higher in patients with high-grade BCL (1.71 ± 2.28 ng/mL, n = 62) than in low-grade BCL (0.75 ± 2.12 ng/mL, n = 52) and healthy controls (0.55 ± 1.58 ng/mL, n = 75) (high-grade BCL vs. low-grade BCL, p = 0.002; high-grade BCL vs. control, p < 0.001, Mann-Whitney U test). In vitro, RNA interference of RanGAP1 showed no effect on LCL but enhanced DLBCL cell death (41% vs. 60%; p = 0.035) and cell-cycle arrest (G0/G1: 39% vs. 49%, G2/M: 19.0% vs. 7.5%; p = 0.030) along with decreased expression of TPX2 and Aurora kinases, the central regulators of mitotic cell division. Furthermore, ON 01910.Na (Estybon), a multikinase inhibitor induced cell death, mitotic cell arrest, and hyperphosphorylation of RanGAP1 in DLBCL cell lines but no effects in normal B and T cells. Therefore, RanGAP1 is a promising marker and therapeutic target for aggressive B-cell lymphoma, especially DLBCL.

AB - Lymphoma-specific biomarkers contribute to therapeutic strategies and the study of tumorigenesis. Diffuse large Bcell lymphoma (DLBCL) is the most common type of malignant lymphoma. However, only 50% of patients experience long-term survival after current treatment; therefore, developing novel therapeutic strategies is warranted. Comparative proteomic analysis of two DLBCL lines with a B-lymphoblastoid cell line (LCL) showed differential expression of Ran GTPase-activating protein 1 (RanGAP1) between them, which was confirmed using immunoblotting. Immunostaining showed that the majority of DLBCLs (92%, 46/50) were RanGAP1+, while reactive lymphoid hyperplasia (n = 12) was RanGAP1+ predominantly in germinal centers. RanGAP1 was also highly expressed in other B-cell lymphomas (BCL, n = 180) with brisk mitotic activity (B-lymphoblastic lymphoma/leukemia: 93%, and Burkitt lymphoma: 95%) or cell-cycle dysregulation (mantle cell lymphoma: 83%, and Hodgkin's lymphoma 91%). Interestingly, serum RanGAP1 level was higher in patients with high-grade BCL (1.71 ± 2.28 ng/mL, n = 62) than in low-grade BCL (0.75 ± 2.12 ng/mL, n = 52) and healthy controls (0.55 ± 1.58 ng/mL, n = 75) (high-grade BCL vs. low-grade BCL, p = 0.002; high-grade BCL vs. control, p < 0.001, Mann-Whitney U test). In vitro, RNA interference of RanGAP1 showed no effect on LCL but enhanced DLBCL cell death (41% vs. 60%; p = 0.035) and cell-cycle arrest (G0/G1: 39% vs. 49%, G2/M: 19.0% vs. 7.5%; p = 0.030) along with decreased expression of TPX2 and Aurora kinases, the central regulators of mitotic cell division. Furthermore, ON 01910.Na (Estybon), a multikinase inhibitor induced cell death, mitotic cell arrest, and hyperphosphorylation of RanGAP1 in DLBCL cell lines but no effects in normal B and T cells. Therefore, RanGAP1 is a promising marker and therapeutic target for aggressive B-cell lymphoma, especially DLBCL.

UR - http://www.scopus.com/inward/record.url?scp=84892416351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892416351&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0079863

DO - 10.1371/journal.pone.0079863

M3 - Article

C2 - 24223200

AN - SCOPUS:84892416351

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 11

M1 - e79863

ER -